PARP cleavage and perturbance in mitochondrial membrane potential by 3-α-propionyloxy-β-boswellic acid results in cancer cell death and tumor regression in murine models

Future Oncology

Volumn 8, Issue 7, 2012, Pages 867-881

  Qurishi, Yasrib ^a   Hamid, Abid ^a   Sharma, Parduman R ^a   Wani, Zahoor Ahmad ^a   Mondhe, Dilip M ^a   Singh, Shashank K ^a   Zargar, Mohmmad Afzal ^b   Andotra, Samar S ^a   Shah, Bhahwal Ali ^a   Taneja, Subhash C ^a   Saxena, Ajit Kumar ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b UNIVERSITY OF KASHMIR   (India)

Author keywords

apoptosis; Boswellia serrata; cancer; chemotherapy

Indexed keywords

3 ALPHA PROPIONYLOXY BETA BOSWELLIC ACID; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL DEATH; CELL ULTRASTRUCTURE; CELLULAR DISTRIBUTION; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; ELECTRON MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SURFACE PROPERTY; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BODY WEIGHT; CARCINOMA, EHRLICH TUMOR; CELL DEATH; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; TRITERPENES;

EID: 84864483510     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.68     Document Type: Article

References (31)

1. Wolin KY, Colditz GA. Implementing chronic disease prevention amongst cancer survivors. J. Intern. Med. 269(1), 85-87 (2011).
2. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull. World Health Organ. 63(6), 965-981 (1985).
3. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 78(5), 431-441 (2005).
4. Dolle L, Depypere HT, Bracke ME. Anti-invasive/anti-metastasis strategies: New roads, new tools and new hopes. Curr. Cancer Drug Targets 6(8), 729-751 (2006).
5. Gullo VP, McAlpine J, Lam KS, Baker D, Petersen F. Drug discovery from natural products. J. Ind. Microbiol. Biotechnol. 33(7), 523-531 (2006).
6. Qurishi Y, Hamid A, Zargar MA, Singh SK, Saxena AK. Potential role of natural molecules in health and disease: Importance of boswellic acid. J. Med. Plant Res. 4(25), 2778-2785 (2010).
7. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee - A randomized double blind placebo controlled trial. Phytomedicine 10(1), 3-7 (2003).
8. Gupta I, Gupta V, Parihar A et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma. Results of a double-blind, placebo-controlled, 6-week clinical study. Eur. J. Med. Res. 3(11), 511-514 (1998).
9. Krieglstein CF, Anthoni C, Rijcken EJ et al. Acetyl-11-keto-beta- boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int. J. Colorectal Dis. 16(2), 88-95 (2001).
10. Hostanska K, Suter A, Melzer J, Saller R. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan®) on human carcinoma cell lines. Anticancer Res. 27(2), 873-881 (2007).
11. Poeckel D, Tausch L, Altmann A et al. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid. Br. J. Pharmacol. 146(4), 514-524 (2005).
12. Burlando B, Parodi A, Volante A, Bassi AM. Comparison of the irritation potentials of Boswellia serrata gum resin and of acetyl-11- keto-beta-boswellic acid by in vitro cytotoxicity tests on human skin-derived cell lines. Toxicol. Lett. 177(2), 144-149 (2008).
13. Raja AF, Ali F, Khan IA, Shawl AS, Arora DS. Acetyl-11-keto-β- boswellic acid (AKBA); targeting oral cavity pathogens. BMC Res. Notes 4, 406 (2011).
14. Hoernlein RF, Orlikowsky T, Zehrer C et al. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J. Pharmacol. Exp. Ther. 288(2), 613-619 (1999).
15. Shah BA, Qazi GN, Taneja SC. Boswellic acids: A group of medicinally important compounds. Nat. Prod. Rep. 26(1), 72-89 (2009).
16. Chashoo G, Singh SK, Mondhe DM et al. Potentiation of the antitumor effect of 11-keto-beta-boswellic acid by its 3-alpha-hexanoyloxy derivative. Eur. J. Pharmacol. 668(3), 390-400 (2011).
17. Houghton P, Fang R, Techatanawat I, Steventon G, Hylands PJ, Lee CC. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 42(4), 377-387 (2007).
18. Khan S, Chib R, Shah BA et al. A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur. J. Pharmacol. 660(2-3), 241-248 (2011).
19. Brown GC, Borutaite V. Nitric oxide, cytochrome c and mitochondria. Biochem. Soc. Symp. 66, 17-25 (1999).
20. Washo-Stultz D, Crowley-Weber CL, Dvorakova K et al. Role of mitochondrial complexes I and II, reactive oxygen species and arachidonic acid metabolism in deoxycholate-induced apoptosis. Cancer Lett. 177(2), 129-144 (2002).
21. Rello S, Stockert JC, Moreno V et al. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 10(1), 201-208 (2005).
22. Legrier ME, Yang CP, Yan HG et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 67(23), 11300-11308 (2007).
23. Xia L, Chen D, Han R, Fang Q, Waxman S, Jing Y. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol. Cancer Ther. 4(3), 381-388 (2005).
24. Smith DM, Kazi A, Smith L et al. A novel beta-lactam antibiotic activates tumor cell apoptotic program by inducing DNA damage. Mol. Pharmacol. 61(6), 1348-1358 (2002).
25. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: A promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem. 8(12), 1487-1503 (2001).
26. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27(41), 5511-5526 (2008).
27. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med. Chem. 9(5), 550-559 (2009).
28. Basnakian AG, James SJ. A rapid and sensitive assay for the detection of DNA fragmentation during early phases of apoptosis. Nucleic Acids Res. 22(13), 2714-2715 (1994).
29. Salido M, Gonzalez JL, Vilches J. Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells. Mol. Cancer Ther. 6(4), 1292-1299 (2007).
30. Wang CY, Mayo MW, Baldwin AS Jr TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 274(5288), 784-787 (1996).
31. Garcia Z, Kumar A, Marques M, Cortes I, Carrera AC. Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J. 25(4), 655-661 (2006).